Vir Biotechnology VIR 深 滬
等待開盤 06-26 09:30:00 美东时间
9.88
-0.070
-0.70%
華盛通- 最 高10.23
- 今 開9.90
- 成交量 133.71万股
- 最 低 9.85
- 昨 收 9.95
- 總市值 16.66亿
- 52周最高 11.66
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 4.155
- 委 比 -39.78%
- 總股本 1.69亿
- 歷史最高 141.01
- 量 比 0.36
- 振 幅 3.82%
- 歷史最低 4.155
- 每 手 1
- 風險率 1.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
Vir Biotechnology Adds Timothy Coughlin to Board, Audit Chair
The latest announcement is out from Vir Biotechnology ( ($VIR) ). On June 9, 20...
06-11 05:41
美股大行评级 | 火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元
火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元；犹他美容(ULTA)惨遭12家大行下调目标价>>
06-04 11:36
Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21
Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $20 to $21.
06-03 22:22
Vir Biotechnology To Present Data From Its Phase 2 SOLSTICE Study Of Obevibart And Elebsiran Combination To Treat Chronic Hepatitis Delta
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL
05-19 04:08
Vir Biotechnology shares are trading lower after the company reported a year-over-year decrease in its Q1 sales results.
Vir Biotechnology shares are trading lower after the company reported a year-ov...
05-08 00:39
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Vir Biotechnology announces annual shareholder meeting
Vir Biotechnology announces annual shareholder meeting Vir Biotechnology scheduled 2026 annual stockholder meeting for May 26, 2026, to be held online. Shareholders will vote on election of three Class I directors: Robert More, Janet Napolitano, Elliott Sigal. Advisory vote set on named executive of
04-16 20:48
Vir Biotech Doses First Patient In Phase 1 Expansion Trial Of VIR-5500 For Metastatic Prostate Cancer
Phase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in both early and late-line metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive
04-13 20:07
